Financial Contrast: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Phibro Animal Health (NASDAQ:PAHC)

Phibro Animal Health (NASDAQ:PAHC) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Phibro Animal Health and Shuttle Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	2	2	0	0	1.50
Shuttle Pharmaceuticals	0	0	0	0	0.00

Phibro Animal Health currently has a consensus price target of $21.00, indicating a potential upside of 12.54%. Given Phibro Animal Health’s stronger consensus rating and higher probable upside, equities analysts plainly believe Phibro Animal Health is more favorable than Shuttle Pharmaceuticals.

Profitability

This table compares Phibro Animal Health and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	1.75%	25.35%	6.21%
Shuttle Pharmaceuticals	N/A	-583.02%	-258.92%

Risk and Volatility

Phibro Animal Health has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500.

Institutional and Insider Ownership

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 39.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Phibro Animal Health and Shuttle Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.11 billion	0.68	$2.42 million	$0.48	38.88
Shuttle Pharmaceuticals	N/A	N/A	-$6.59 million	($4.15)	-0.11

Phibro Animal Health has higher revenue and earnings than Shuttle Pharmaceuticals. Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Phibro Animal Health beats Shuttle Pharmaceuticals on 12 of the 12 factors compared between the two stocks.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.